Welcome to our dedicated page for Protara Therapeutics SEC filings (Ticker: TARA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Protara Therapeutics, Inc. filings document a Nasdaq-listed, Delaware clinical-stage biotechnology company developing TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride for patients receiving parenteral support. Form 8-K disclosures include clinical-data updates, Regulation FD materials, financial results, investor presentations, and business updates related to the company's investigational programs.
The filing record also covers Protara's capital structure and governance, including common stock registered on The Nasdaq Global Market, public offering and underwriting agreements, warrant-related disclosures, and proxy materials for annual stockholder voting. Proxy filings describe board elections, executive compensation matters, equity plans, audit oversight, and other corporate-governance proposals.
Janus Henderson Group Ltd. reports passive ownership of common stock of Protara Therapeutics, Inc. under a Schedule 13G/A. Investment adviser affiliates of Janus Henderson, acting as asset managers for client accounts referred to as Managed Portfolios, may be deemed the beneficial owners of 4,696,709 shares of Protara common stock, representing 8.4% of the class.
Janus Henderson and its asset managers have no sole voting or dispositive power but hold shared voting and shared dispositive power over 4,696,709 shares, reflecting authority exercised on behalf of clients. The asset managers disclaim rights to receive dividends or sale proceeds, which belong to the Managed Portfolios. Among these, Janus Henderson Biotech Innovation Master Fund Ltd. alone has the right to receive dividends or sale proceeds from more than five percent of Protara’s common stock, while not being considered a separate reporting person due to delegated investment and voting discretion.
Protara Therapeutics, Inc. reported a larger loss as it continued funding multiple late‑stage development programs. For the six months ended June 30, 2026, net loss was $39.5 million compared with $26.9 million a year earlier, driven by higher research and development and personnel costs. Total operating expenses rose to $43.0 million, including $30.5 million in research and development and $12.4 million in general and administrative expenses.
Liquidity remains solid for a clinical‑stage company. As of June 30, 2026, Protara held $161.9 million in unrestricted cash, cash equivalents and marketable debt securities, total assets of $176.1 million, and stockholders’ equity of $161.3 million. Management believes these resources are sufficient to fund estimated needs for at least 12 months while advancing TARA‑002 in bladder cancer and lymphatic malformations and IV Choline Chloride in a Phase 3 trial for patients on parenteral support.
Protara Therapeutics, Inc. reported second quarter 2026 results and outlined progress across its late-stage pipeline. For the quarter ended June 30, 2026, the company recorded a net loss of $21.7 million compared with $15.0 million a year earlier, driven by higher research and development spending as programs advanced. Research and development expenses were $17.0 million versus $10.8 million in the prior-year quarter, while general and administrative expenses were $6.4 million versus $5.8 million.
Cash, cash equivalents and investments totaled approximately $162 million as of June 30, 2026, which the company expects will support planned operations into 2028. Protara plans several milestones: completion of enrollment in the BCG-unresponsive registrational cohort of the ADVANCED-2 trial and interim results from the THRIVE-3 registrational trial in 4Q 2026; completion of enrollment in the STARBORN-1 trial in lymphatic malformations in 4Q 2026; and a planned Biologics License Application submission for TARA-002 in lymphatic malformations in the second half of 2027.
Protara Therapeutics disclosure: reporting groups state shared beneficial ownership positions. Integrated Core Strategies (US) LLC reports 2,879,674 shares with shared voting and dispositive power, equal to 5.1%. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report 3,201,936 shares with shared voting and dispositive power, equal to 5.7%. The filing is an Amendment No. 1 to a Schedule 13G/A and includes a Joint Filing Agreement dated July 6, 2026. Signatures are provided by Gil Raviv and Israel A. Englander.
Protara Therapeutics, Inc. CEO Jesse Shefferman reported multiple equity transactions in Protara common stock. On June 29, 2026, he exercised stock options to acquire 215,687 shares at an exercise price of $1.91 per share and sold 215,687 shares in open-market transactions at a weighted average price of $4.09 per share, with individual sale prices ranging from $4.03 to $4.14.
On June 30, 2026, Shefferman made bona fide gift transfers totaling 30,000 shares of common stock in four separate transactions. Following these transactions, he holds 691,832 shares directly and 300,000 shares indirectly through The Samhold Family Trust, and 141,313 stock options with a $1.91 exercise price expiring on January 18, 2034.
Protara Therapeutics, Inc. reported that its Chief Medical Officer, Leonardo Viana Nicacio, M.D., has resigned from the company to explore other opportunities, effective June 26, 2026. His responsibilities will transition to Carla Beckham, M.D., the company’s Lead Medical Director and Head of Clinical Development, under the continued oversight of Jacqueline Zummo, Ph.D., Chief Research & Development Officer. This represents a leadership change in the company’s medical and clinical development organization.
Protara Therapeutics director Richard S. Levy received a stock option grant covering 31,000 shares of common stock. The option has an exercise price of $3.94 per share and was granted as a derivative security.
According to the terms, the 31,000 options are scheduled to vest in full on the first anniversary of the grant date, provided Dr. Levy continues to serve on the board through that date. The options will also vest in full upon a Change of Control. Following this grant, his reported derivative holdings from this award total 31,000 options.
Protara Therapeutics director Michael Edward Solomon received a stock option grant for 31,000 shares of Common Stock. The option has an exercise price of $3.94 per share and was granted as a Stock Option (Right to Buy). It vests in full on the first anniversary of the grant date, subject to his continued service on the Board, and will also vest in full upon a Change of Control. Following this award, he holds 31,000 option shares related to this grant, which expires on June 14, 2036.
Protara Therapeutics director Cynthia Smith received a grant of stock options as equity compensation. She was awarded options covering 31,000 shares of common stock at an exercise price of $3.94 per share. These options vest in full on the first anniversary of the grant date, provided she continues to serve on the board, and will also fully vest upon a Change of Control.